Novel oral anticoagulants and reversal agents: Considerations for clinical development

View Paper Here

Troy C. Sarich, PhD, a Jonathan H. Seltzer,MD, b Scott D. Berkowitz,MD, c James Costin’,MD, d John T. Curnutte,MD, e C. Michael Gibson, MD, f Maureane Hoffman, MD, PhD, g Edvardas Kaminskas, MD, h Mitchell W. Krucoff, MD, i Jerrold H. Levy, MD, j Paul D. Mintz, MD, k Paul A. Reilly, PhD, l Philip T. Sager, MD, m Daniel E. Singer, MD, n Norman Stockbridge, MD, PhD, o Jeffrey I. Weitz, DM, p and Peter R. Kowey, MD q Titusville, NJ; Wynnewood, PA; Whippany, NJ; Danbury, CT; South San Francisco, CA; Boston, MA; Durham, NC; Silver Spring, MD; Ridgefield, CT; Hamilton, ON; and Philadelphia, PA